D.A. Davidson & CO. Makes New $1.02 Million Investment in BioLife Solutions, Inc. (NASDAQ:BLFS)

D.A. Davidson & CO. purchased a new position in shares of BioLife Solutions, Inc. (NASDAQ:BLFS) during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 40,660 shares of the medical equipment provider’s stock, valued at approximately $1,018,000. D.A. Davidson & CO. owned about 0.09% of BioLife Solutions as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently modified their holdings of BLFS. The Manufacturers Life Insurance Company grew its position in BioLife Solutions by 40.8% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 19,463 shares of the medical equipment provider’s stock worth $487,000 after purchasing an additional 5,638 shares during the last quarter. Alpha DNA Investment Management LLC acquired a new stake in shares of BioLife Solutions during the third quarter worth $467,000. Cerity Partners LLC grew its holdings in shares of BioLife Solutions by 6.6% during the third quarter. Cerity Partners LLC now owns 44,914 shares of the medical equipment provider’s stock valued at $1,125,000 after buying an additional 2,776 shares during the last quarter. Eagle Asset Management Inc. grew its holdings in shares of BioLife Solutions by 2.9% during the third quarter. Eagle Asset Management Inc. now owns 352,897 shares of the medical equipment provider’s stock valued at $9,221,000 after buying an additional 10,091 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. increased its position in shares of BioLife Solutions by 3.1% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 319,959 shares of the medical equipment provider’s stock valued at $8,012,000 after acquiring an additional 9,750 shares during the period. Institutional investors and hedge funds own 93.24% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have commented on BLFS shares. Craig Hallum lifted their price target on BioLife Solutions from $30.00 to $32.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. TD Cowen upped their target price on BioLife Solutions from $28.00 to $31.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th. Northland Securities increased their price target on shares of BioLife Solutions from $26.00 to $28.00 and gave the stock an “outperform” rating in a report on Friday, August 9th. Finally, HC Wainwright decreased their price objective on shares of BioLife Solutions from $29.00 to $27.00 and set a “buy” rating for the company in a research note on Monday, November 18th. One equities research analyst has rated the stock with a sell rating and six have issued a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $27.50.

Insider Activity at BioLife Solutions

In other BioLife Solutions news, CRO Garrie Richardson sold 3,070 shares of BioLife Solutions stock in a transaction on Monday, September 16th. The shares were sold at an average price of $25.12, for a total value of $77,118.40. Following the completion of the transaction, the executive now owns 114,773 shares of the company’s stock, valued at approximately $2,883,097.76. The trade was a 2.61 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Aby J. Mathew sold 10,000 shares of the stock in a transaction dated Tuesday, October 15th. The stock was sold at an average price of $23.28, for a total transaction of $232,800.00. Following the sale, the executive vice president now directly owns 317,716 shares in the company, valued at approximately $7,396,428.48. The trade was a 3.05 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 71,313 shares of company stock worth $1,572,899 in the last three months. Company insiders own 2.20% of the company’s stock.

BioLife Solutions Trading Up 1.1 %

BioLife Solutions stock opened at $27.47 on Monday. The firm has a market cap of $1.27 billion, a PE ratio of -25.92 and a beta of 1.88. BioLife Solutions, Inc. has a 12 month low of $11.91 and a 12 month high of $28.88. The stock’s 50 day simple moving average is $24.23 and its two-hundred day simple moving average is $23.24. The company has a current ratio of 2.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.03.

BioLife Solutions Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.